Cerebrolysin: Porcine Brain Neuropeptide Mixture
Last updated: October 2026
Cerebrolysin (FPF 1070) is a mixture of low-molecular-weight peptides and amino acids derived from porcine brain. It is widely used for acute ischaemic stroke in Russia, Eastern Europe, China, and other Asian and post-Soviet countries, but it is not approved in the United States. Here is what two Cochrane reviews found, benefits and harms included.
Cochrane 2023
Participants
Cochrane 2019
What Is Cerebrolysin?
Cerebrolysin (FPF 1070) is a porcine brain-derived peptide mixture from EVER Neuro Pharma (Austria), studied mainly in acute ischaemic stroke and vascular dementia.
A mixture of low-molecular-weight peptides and amino acids derived from porcine brain tissue.
Described by Cochrane reviewers as having potential neuroprotective properties. In acute stroke trials that potential did not show up as a benefit on death.
Said to have neurotrophic activity. In vascular dementia, the evidence for a cognitive benefit is weak and any effect may be too small to matter clinically.
Given by injection under medical supervision (in vascular dementia, as a series of daily IV infusions). It is not an oral product, which sets it apart from oral nootropics.
What the Research Shows
What two Cochrane systematic reviews found.
Context: Cerebrolysin is widely used in Russia, Eastern Europe, China, and other Asian and post-Soviet countries. In the stroke review, the manufacturer supported three of the trials, and most risk-of-bias judgements were unclear. It is not FDA approved.
Dosing & Administration
Prescription-only and given by clinicians. This page does not offer a self-administration protocol.
- Given by injection (daily IV infusions in the dementia trials)
- Dose and course length vary by country and indication
- Set and supervised by the prescribing physician
- Treatment started within 48 hours of stroke onset
- No benefit on all-cause death vs placebo or no treatment
- The rise in non-fatal serious adverse events was more prominent with 30 mL/day for 10 days (RR 2.87)
- Monitored in a clinical setting
Study Citations
Key Takeaways
- Widely used for acute stroke in Russia, Eastern Europe, China, and other Asian countries
- Acute stroke: probably no benefit on all-cause death (Cochrane 2023, moderate certainty)
- Acute stroke: more non-fatal serious adverse events with Cerebrolysin (RR 2.39, moderate certainty)
- Possible small cognitive benefit in mild-moderate vascular dementia (Cochrane 2019, very low-quality evidence)
- Not FDA approved — unavailable in US pharmacies
- Requires injection, not oral
- Long-term effects unclear; dementia-trial follow-up ranged from 15 days to three years
- Whether it helps Alzheimer's disease or brain injury is not covered by the reviews cited here
- Requires prescription and medical supervision
🛒 Recommended Products
General supplements some readers ask about. These are not part of Cerebrolysin therapy, which must be prescribed.
Want the Complete Protocol Guide?
Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place.
Get the Guide — $19 (normally $29) →
New to peptides? Start with the $19 Buyer’s Playbook →
Cerebrolysin is NOT FDA approved and not available in US pharmacies. It requires prescription and must be administered by medical professionals by injection. This page is for educational purposes only. Always consult a qualified healthcare provider. Not Available in US
Get the Free 2026 Peptide Protocol Stack
Twelve compounds across four pillars — metabolic, tissue repair, longevity, cognitive. Citations included, formatted to print. Sent straight to your inbox.